经济新形势下医药制造业上市公司财务竞争力实证分析

Research on Financial Competitiveness Evaluation of Pharmaceutical Manufacturing Listed Companies under the Background of Epidemic

医药制造业的发展是保障和提升人民健康水平的重要基础。近年来,随着全球健康需求的变化和科技的进步,医药制造行业面临着不断变化的市场环境和激烈的竞争。为了评价和比较不同医药制造公司在新形势下的竞争力水平,本文基于100家医药制造业上市公司2020~2022年的财务数据,从盈利能力、偿债能力、发展能力、营运能力、研发投入能力五个方面构建了财务竞争力评价指标体系,并运用因子分析法和K-means聚类分析法进行深入比较和分析。本研究结果将有助于医药制造企业识别自身的竞争优势与劣势,进而制定相应的发展战略,推动整个行业竞争力的提升。

The development of pharmaceutical manufacturing industry is an important foundation for safeguarding and improving people’s health. In recent years, with the change of global health demand and the progress of science and technology, the pharmaceutical manufacturing industry is facing a constantly changing market environment and fierce competition. In order to evaluate and compare the competitiveness level of different pharmaceutical manufacturing companies in the new situation, based on the 2020~2022 financial data of 100 pharmaceutical manufacturing industry listed companies, this paper constructs a financial competitiveness evaluation index system from five aspects: profitability, debt paying ability, development ability, operation ability and R&D investment ability. The factor analysis method and K-means clustering analysis method are used for in-depth comparison and analysis. The results of this research will help pharmaceutical manufacturers’ industry companies to recognize their own competitive advantages and disadvantages, so as to formulate corresponding development strategies and promote the competitiveness of the whole industry.